Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.

Oligny-Longpré G, Corbani M, Zhou J, Hogue M, Guillon G, Bouvier M.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):E1028-37. doi: 10.1073/pnas.1112422109. Epub 2012 Apr 9.

2.

Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.

Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M.

Mol Pharmacol. 2010 May;77(5):836-45. doi: 10.1124/mol.109.061804. Epub 2010 Feb 16.

3.

Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor.

Galandrin S, Oligny-Longpré G, Bonin H, Ogawa K, Galés C, Bouvier M.

Mol Pharmacol. 2008 Jul;74(1):162-72. doi: 10.1124/mol.107.043893. Epub 2008 Apr 10.

4.

The evasive nature of drug efficacy: implications for drug discovery.

Galandrin S, Oligny-Longpré G, Bouvier M.

Trends Pharmacol Sci. 2007 Aug;28(8):423-30. Epub 2007 Jul 19. Review.

PMID:
17659355
5.

The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling.

Charest PG, Oligny-Longpré G, Bonin H, Azzi M, Bouvier M.

Cell Signal. 2007 Jan;19(1):32-41. Epub 2006 Jun 3.

PMID:
16857342

Supplemental Content

Loading ...
Support Center